Contamination rates were extrapolated based on linkage to general practitioner laboratories

and questionnaires in the Rotterdam ERSPC section. The mortality difference between screening and control arms was then calculated after adjustment for these noncompliance and contamination rates using the method of Cuzick and colleagues.4 As compared with Inhibitors,research,lifescience,medical the ITT estimate of 20%,1 adjustment for noncompliance led to a 30% relative increase in the mortality benefit of screening (RR 0.73; 95% CI, 0.58–0.93). After additional adjustment for contamination, the authors estimated that screening reduced cancer-specific mortality by 31% to 33%, as compared with no screening. There are several limitations to this study, Inhibitors,research,lifescience,medical including the extrapolation of Rotterdam data on contamination to the remaining 6 countries with potentially

differing frequencies of opportunistic prostate-specific antigen (PSA) testing. In addition, noncompliance was exclusively based on the initial screening round. Further analysis of the influence of the actual frequency and timing of screening on mortality would be informative. Finally, divergence from a strict ITT analysis obviates the main advantage of randomization, Inhibitors,research,lifescience,medical and introduces the potential for bias associated with observational studies. Despite these inherent limitations, this study provided an interesting estimation of the true mortality benefit associated with screening. Indeed, these results support the initial hypothesis that the prostate cancer mortality reduction of 20% at 9 years in the ITT analysis Inhibitors,research,lifescience,medical may have been diluted by noncompliance and contamination. Taking these factors into account, PSA screening was associated with up to a 33% prostate cancer mortality reduction at 9 years. Prostate Cancer Mortality in Screen and Clinically Detected Prostate Cancer: Estimating the Screening Benefit van Leeuwen PJ, Connolly

D, Gavin A, et al. Eur J Cancer 2010;46:377–383.383 [PubMed]. Inhibitors,research,lifescience,medical This study attempted to estimate the true mortality benefit of PSA screening using an alternate methodology. Rather than attempting to adjust for contamination within the ERSPC itself, van Leeuwen and colleagues identified an outside control population from Northern Ireland with even lower rates of screening Ketanserin to serve as a comparison group. Specifically, 11,970 men aged 55 to 74 years from the screening arm of the Rotterdam ERSPC section (1997–1999) were compared with 133,287 men of the same age from the Northern Ireland population registry (1998–1999). Approximate frequencies of PSA testing in these 2 groups were 94.2% and 6%, respectively. Overall, prostate cancer was selleck compound diagnosed in 1153 (9.6%) men from the Rotterdam ERSPC and 3962 (3.0%) men from Northern Ireland. Screening was associated with a 53% reduction in metastatic disease at diagnosis (0.1% vs 0.6%; P < .001), and a 37% reduction in death from prostate cancer (0.29% vs 0.47%; P = .008), compared with the group from Northern Ireland.